2024-04-22 12:03:00 ET
Summary
- The stock of Gilead Sciences, Inc. has underperformed the market substantially over the past decade, but there are some signs developing of a potential bottom.
- The stock offers a high dividend yield of 4.61% and is trading at a low valuation compared to its peers.
- Gilead is a leader in the HIV space, and its oncology revenues are growing rapidly. The company also has a large pipeline and recently acquired CymaBay Therapeutics.
- An analysis of Gilead Sciences follows in the paragraphs below.
Today, we put Gilead Sciences, Inc. ( GILD ) in the spotlight for the first time in years. As can be seen in the chart below, the stock has done little for its shareholders over the past decade....
Read the full article on Seeking Alpha
For further details see:
Gilead Sciences: Some Signs Of An Impending Bottom